Epithelial-to-mesenchymal transition (EMT) is a malignant cancer phenotype characterized
by augmented invasion and metastasis, chemoresistance, and escape from host-immunity …

Resistance to docetaxel is a major clinical problem in advanced prostate cancer. The
overexpression of AXL receptor tyrosine kinase (AXL) has been correlated with …

Prostate cancer (PC) remains a widespread malignancy in men. Since the
androgen/androgen receptor (AR) axis is associated with the pathogenesis of prostate …

One of the main problems with the treatment of metastatic prostate cancer is that, despite an
initial positive response, the majority of patients develop resistance and progress. In …

TMPRSS2-ERG rearrangement is a genetic alteration exclusive to prostate cancer,
associated with taxane resistance in preclinical models. Its detection in blood samples of …

Epithelial–mesenchymal transition (EMT) has recently been associated with tumor
progression, metastasis, and chemotherapy resistance in several tumor types. We …

Androgens regulate biological pathways to promote proliferation, differentiation, and survival
of benign and malignant prostate tissue. Androgen receptor (AR) targeted therapies exploit …

Castration-resistant prostate cancer (CRPC) remains a major clinical challenge because of
the lack of effective targeted therapy for its treatment. The mechanism underlying how CRPC …

Metastasis causes more than 90% of cancer-related deaths and most prostate cancer (PCa)
patients also die from metastasis. The 'metastatic cascade'is a complex biological process …

Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant
survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the …